A chimeric cell adhesion molecule mediates homing of lymphocytes to vascularized tumors

Cancer Research

Volumn 59, Issue 20, 1999, Pages 5255-5263

  Wiedle, Guido ^a   Johnson Léger, Caroline ^a   Imhof, Beat A ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CHIMERIC PROTEIN; INTEGRIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHICKEN; CONTROLLED STUDY; LUNG CARCINOMA; LYMPHOCYTE HOMING; LYMPHOID CELL; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD31; BASE SEQUENCE; CELL MOVEMENT; CHICKENS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; PEPTIDES; RECEPTORS, VITRONECTIN; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

EID: 0345426309     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Butcher, E. C., and Picker, L. J. Lymphocyte homing and homeostasis. Science (Washington DC), 272: 60-66, 1996.
2. Dunon, D., Piali, L., and Imhof, B. A. To stick or not to stick: the new leukocyte homing paradigm, Curr. Opin. Cell Biol., 8: 714-723, 1996.
3. Springer, T. A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell, 76: 301-314, 1994.
4. Griffioen, A. W., Damen, C. A., Blijham, G. H., and Groenewegen, G. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood, 88: 667-673, 1996.
5. Piali, L., Fichtel, A., Terpe, H. J., Imhof, B. A., and Gisler, R. H. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J. Exp. Med., 181: 811-816, 1995.
6. Griffioen, A. W., Damen, C. A., Martinotti, S., Blijham, G. H., and Groenewegen, G. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res., 56: 1111-1117, 1996.
7. Hellwig, S. M., Damen, C. A., van Adrichem, N. P., Blijham, G. H., Groenewegen, G., and Griffioen, A. W. Endothelial CD34 is suppressed in human malignancies: role of angiogenic factors. Cancer Lett., 120: 203-211, 1997.
8. Battegay, E. J. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J. Mol. Med., 73: 333-346, 1995.
9. Baillie, C. T., Winslet, M. C., and Bradley, N. J. Tumour vasculature-a potential therapeutic target. Br. J. Cancer, 72: 257-267, 1995.
10. Bicknell, R., and Harris, A. L. Mechanisms and therapeutic implications of angio-genesis. Curr. Opin. Oncol., 8: 60-65, 1996.
11. Fan, T. P., Jaggar, R., and Bicknell, R. Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol. Sci., 16: 57-66, 1995.
12. Risau, W. Mechanisms of angiogenesis. Nature (Lond.), 386: 671-674, 1997.
13. Brooks, P. C., Clark, R. A., and Cheresh, D. A. Requirement of vascular integrin αvβ3 for angiogenesis. Science (Washington DC), 264: 569-571, 1994.
14. Max, R., Gerritsen, R. R., Nooijen, P. T., Goodman, S. L., Sutter, A., Keilholz, U., Ruiter, D. J., and De Waal, R. M. Immunohistochemical analysis of integrin αvβ3 expression on tumor-associated vessels of human carcinomas [published erratum appears in Int. J. Cancer, 72: 706-707, 1997]. Int. J. Cancer, 71: 320-324, 1997.
15. Brooks, P. C., Stromblad, S., Klemke, R., Visscher, D., Sarkar, F. H., and Cheresh, D. A. Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin [see comments]. J. Clin. Investig., 96: 1815-1822, 1995.
16. Brooks, P. C., Montgomery, A. M., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., and Cheresh, D. A. Integrin αvβ3 antagonists promole tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 79: 1157-1164, 1994.
17. Hammes, H. P., Brownlee, M., Jonczyk, A., Sutter, A., and Preissner, K. T. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat. Med., 2: 529-533, 1996.
18. Eliceiri, B. P., Klemke, R., Stromblad, S., and Cheresh, D. A. Integrin αvβ3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis, J. Cell Biol., 140: 1255-1263, 1998.
19. Gasparini, G., Brooks, P. C., Biganzoli, E., Vermeulen, P. B., Bonoldi, E., Dirix, L. Y., Ranieri, G., Miceli, R., and Cheresh, D. A. Vascular integrin α(v)β3: a new prognostic indicator in breast cancer. Clin. Cancer Res., 4: 2625-2634, 1998.
20. Gould, R. J., Polokoff, M. A., Friedman, P. A., Huang, T. F., Holt, J. C., Cook, J. J., and Niewiarowski, S. Disintegrins: a family of integrin inhibitory proteins from viper venoms. Proc. Soc. Exp. Biol. Med., 195: 168-171, 1990.
21. Juliano, D., Wang, Y., Marcinkiewicz, C., Rosenthal, L. A., Stewart, G. J., and Niewiarowski, S. Disintegrin interaction with αvβ3 integrin on human umbilical vein endothelial cells: expression of ligand-induced binding site on β3 subunit. Exp. Cell Res., 225: 132-142, 1996.
22. Lu, X., Rahman, S., Kakkar, V. V., and Authi, K. S. Substitutions of proline 42 to alanine and methionine 46 to asparagine around the RGD domain of the neurotoxin dendroaspin alter its preferential antagonism to that resembling the disintegrin elegantin. J. Biol. Chem., 271: 289-294, 1996.
23. Adler, M., Lazarus, R. A., Dennis, M. S., and Wagner, G. Solution structure of kistrin, a potent platelet aggregation inhibitor and GP IIb-IIIa antagonist. Science (Washington DC), 253: 445-448, 1991.
24. Adler, M., Carter, P., Lazarus, R. A., and Wagner, G. Cysteine pairing in the glycoprotein IIbIIIa antagonist kistrin using NMR, chemical analysis, and structure calculations. Biochemistry, 32: 282-289, 1993.
25. Jones, J. I., Prevette, T., Gockerman, A., and Clemmons, D. R. Ligand occupancy of the αvβ3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor. Proc. Natl. Acad. Sci. USA, 93: 2482-2487, 1996.
26. Bird, I. N., Taylor, V., Newton, J. P., Spragg, J. H., Simmons, D. L., Salmon, M., and Buckley, C. D. Homophilic PECAM-1 (CD31) interactions prevent endothelial cell apoptosis but do not support cell spreading or migration. J. Cell Sci., 112: 1989-1997, 1999.
27. Pear, W. S., Nolan, G. P., Scott, M. L., and Baltimore, D. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA, 90: 8392-8396, 1993.
28. Piali, L., Hammel, P., Uherek, C., Bachmann, F., Gisler, R. H., Dunon, D., and Imhof, B. A. CD31/PECAM-1 is a ligand for αvβ3 integrin involved in adhesion of leukocytes to endothelium. J. Cell Biol., 130: 451-460, 1995.
29. Barazzone, C., Tacchini-Cottier, F., Vesin, C., Rochat, A. F., and Piguet, P. F. Hyperoxia induces platelet activation and lung sequestration: an event dependent on tumor necrosis factor-α and CD11a. Am. J. Respir. Cell Mol. Biol., 15: 107-114, 1996.
30. Piguet, P. F., Vesin, C., Ryser, J. E., Senaldi, G., Grau, G. E., and Tacchini-Cottier, F. An effector role for platelets in systemic and local lipopolysaccharide-induced toxicity in mice, mediated by a CD11a- and CD54-dependent interaction with endothelium. Infect. Immun., 61: 4182-4187, 1993.
31. Grau, G. E., Tacchini-Cottier, F., Vesin, C., Milon, G., Lou, J. N., Piguet, P. F., and Juillard, P. TNF-induced microvascular pathology: active role for platelets and importance of the LFA-1/ICAM-1 interaction. Eur. Cytokine Netw., 4: 415-419, 1993.
32. Hodivala-Dilke, K. M., McHugh, K. P., Tsakiris, D. A., Rayburn, H., Crowley, D., Ullman-Cullere, M., Ross, F. P., Coller, B. S., Teitelbaum, S., and Hynes, R. O. β3-Integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J. Clin. Investig., 103: 229-238, 1999.
33. Bader, B. L., Rayburn, H., Crowley, D., and Hynes, R. O. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all av integrins Cell, 95: 507-519, 1998.
34. Conforti, G., Dominguez-Jimenez, C., Zanetti, A., Gimbrone, M. A., Jr., Cremona, O., Marchisio, P. C., and Dejana, E. Human endothelial cells express integrin receptors on the luminal aspect of their membrane. Blood, 80: 437-446, 1992.
35. Pasqualini, R., Koivunen, E., and Ruoslahti, E, αv integrins as receptors for tumor targeting by circulating ligands [see comments]. Nat. Biotechnol., 15: 542-546, 1997.
36. Sipkins, D. A., Cheresh, D. A., Kazemi, M. R., Nevin, L. M., Bednarski, M. D., and Li, K. C. Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging. Nat. Med., 4: 623-626, 1998.
37. Arap, W., Pasqualini, R., and Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model [see comments]. Science (Washington DC), 279: 377-380, 1998.
38. Molema, G., and Griffioen, A. W. Rocking the foundations of solid tumor growth by attacking the tumor's blood supply. Immunol. Today, 19: 392-394, 1998.
39. Felding-Habermann, B., and Cheresh, D. A. Vitronectin and its receptors. Curr. Opin. Cell Biol., 5: 864-868, 1993.
40. Seiffert, D., and Smith, J. W. The cell adhesion domain in plasma vitronectin is cryptic. J. Biol. Chem., 272: 13705-13710, 1997.
41. Adler, M., Lazarus, R. A., Dennis, M. S., and Wagner, G. Solution structure of kistrin, a potent platelet aggregation inhibitor and GP IIb-IIIa antagonist. Science (Washington DC), 253: 445-448, 1991.
42. Pellegatta, F., Chierchia, S. L., and Zocchi, M. R. Functional association of platelet endothelial cell adhesion molecule-1 and phosphoinositide 3-kinase in human neutrophils. J. Biol. Chem., 273: 27768-27771, 1998.
43. Tanaka, Y., Albelda, S. M., Horgan, K. J., van Seventer, G. A., Shimizu, Y., Newman, W., Hallam, J., Newman, P. J., Buck, C. A., and Shaw, S. CD31 expressed on distinctive T cell subsets is a preferential amplifier of β1 integrin-mediated adhesion. J. Exp. Med., 176: 245-253, 1992.
44. Leavesley, D. I., Oliver, J. M., Swart, B. W., Berndt, M. C., Haylock, D. N., and Simmons, P. J. Signals from platelet/endothelial cell adhesion molecule enhance the adhesive activity of the very late antigen-4 integrin of human CD34+ hemopoietic progenitor cells. J. Immunol., 153: 4673-4683, 1994.
45. Piali, L., Albelda, S. M., Baldwin, H. S., Hammel, P., Gisler, R. H., and Imhof, B. A. Murine platelet endothelial cell adhesion molecule (PECAM-1)/CD31 modulates β2 integrins on lymphokine-activated killer cells. Eur. J. Immunol., 23: 2464-2471. 1993.
46. Poggi, A., Panzeri, M. C., Moretta, L., and Zocchi, M. R. CD31-triggered rearrangement of the actin cytoskeleton in human natural killer cells. Eur. J. Immunol., 26: 817-824, 1996.
47. Berman, M. E., and Muller, W. A. Ligation of platelet/endothelial cell adhesion molecule 1 (PECAM- 1/CD31) on monocytes and neutrophils increases binding capacity of leukocyte CR3 (CD11b/CD18). J. Immunol., 154: 299-307, 1995.
48. Berman, M. E., Xie, Y., and Muller, W. A. Roles of platelet/endothelial cell adhesion molecule-1 (PECAM-1, CD31) in natural killer cell transendothelial migration and β2 integrin activation. J. Immunol., 156: 1515-1524, 1996.
49. Horenslein, A. L., Stockinger, H., Imhof, B. A., and Malavasi, F. CD38 binding to human myeloid cells is mediated by mouse and human CD31. Biochem. J., 330: 1129-1135, 1998.
50. Albelda, S. M., Muller, W. A., Buck, C. A., and Newman, P. J. Molecular and cellular properties of PECAM-1 (endoCAM/CD31): a novel vascular cell-cell adhesion molecule. J. Cell Biol., 114: 1059-1068, 1991.
51. Buckley, C. D., Doyonnas, R., Newton, J. P., Blystone, S. D., Brown, E. J., Watt, S. M., and Simmons, D. L. Identification of αvβ3 as a heterotypic ligand for CD31/PECAM- 1. J. Cell Sci., 109: 437-445, 1996.
52. Friedlander, M., Brooks, P. C., Shaffer, R. W., Kincaid, C. M., Varner, J. A., and Cheresh, D. A. Definition of two angiogenic pathways by distinct av integrins. Science (Washington DC), 270: 1500-1502, 1995.